Jassin, M.* , E Silva, B.* , Ormenese, S., Baron, F., Ehx, G.* , & Caers, J.*. (13 March 2026). Comparable restimulation of human T cells activated with CD3/CD28 beads versus soluble antibody complexes. Scientific Reports, 16 (1). doi:10.1038/s41598-026-43542-4 * These authors have contributed equally to this work. |
E Silva, B.* , Daubry, A.* , Faville, C.* , De Voeght, A., Foguenne, J., Jassin, M., Kwan, O., Correia Da Cruz, L., Carriglio, G., Charles, S., Baron, F., Caers, J., Gothot, A., & Ehx, G. (2026). Biases introduced by Ficoll-based isolation in acute myeloid leukemia sample analyses support the use of hemolysis. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/342923. doi:10.64898/2026.02.11.705243 * These authors have contributed equally to this work. |
Jassin, M., Onkelinx, C., Bocuzzi, V., E Silva, B., Kwan, O., Block, A., Dubois, S., Daulne, C., Marcion, G., Ormenese, S., Di Valentin, E., Baron, F., GREGOIRE, C., Ehx, G., Nguyen, T. T., & Caers, J. (08 December 2025). Comparing a Novel Anti-BCMA NanoCAR with a Conventional ScFv-Based CAR for the Treatment of Multiple Myeloma. Cells, 14 (24), 1944. doi:10.3390/cells14241944 |
Jassin, M., Onkelinx, C., E Silva, B., Bocuzzi, V., Block, A., Marcion, G., Baron, F., Di Valentin, E., Ehx, G., Nguyen, T. T., & Caers, J. (18 November 2025). Design of a novel NanoCAR construct that compares well with a conventional ScFv-based CAR targeting BCMA on multiple myeloma [Poster presentation]. Bis annual meeting. |
Faville, C.* , E Silva, B.* , Baron, F., & Ehx, G. (19 March 2025). Use of Human Acute Myeloid Leukemia Cells to Study Graft-Versus-Leukemia Immunity in Xenogeneic Mouse Models of Graft-Versus-Host Disease. Methods in Molecular Biology, 2907, 359 - 375. doi:10.1007/978-1-0716-4430-0_17 * These authors have contributed equally to this work. |
Jassin, M., E Silva, B., Bocuzzi, V., Block, A., Marcion, G., Baron, F., Di Valentin, E., Ehx, G., Caers, J., Nguyen, T. T., & Onkelinx, C. (06 February 2025). CAR-T and nanoCAR-T for multiple myeloma: Does smaller mean smarter ? [Poster presentation]. 7th European CAR T-cell Meeting, Strasbourg, France. |
Jassin, M., Onkelinx, C., E Silva, B., Bocuzzi, V., Marcion, G., Ehx, G., Baron, F., Di Valentin, E., Caers, J., & Nguyen, T. T. (29 January 2025). CAR-T and nanoCAR-T for multiple myeloma: Does smaller mean smarter ? [Poster presentation]. Séminaire Télévie 2025, Liège, Belgium. |
E Silva, B., Daubry, A., Faville, C., Jassin, M., Baron, F., & Ehx, G. (2024). IFN-γ predisposes acute myeloid leukemia to therapy resistance. European Journal of Immunology. doi:10.1002/eji.202470200 |
Jassin, M., E Silva, B., Bocuzzi, V., Marcion, G., Ehx, G., Baron, F., Di Valentin, E., Caers, J., Nguyen, T. T., & Onkelinx, C. (31 May 2024). CAR-T and nanoCAR-T for multiple myeloma: Does smaller mean smarter ? [Poster presentation]. Recent insights into Immuno-Oncology, Anvers, Belgium. |
Jassin, M., Chloé Onkelinx, E Silva, B., Bocuzzi, V., Marcion, G., Ehx, G., Baron, F., Di Valentin, E., Caers, J., & Nguyen, T. T. (15 February 2024). CAR-T and nanoCAR-T for multiple myeloma: Does smaller mean smarter ? [Poster presentation]. EBMT - EHA 6th European CAR T-cell Meeting, Valence, Spain. |
Jassin, M., Chloé Onkelinx, E Silva, B., Bocuzzi, V., Marcion, G., Ehx, G., Baron, F., Di Valentin, E., Caers, J., & Nguyen, T. T. (06 February 2024). CAR-T and nanoCAR-T for multiple myeloma: Does smaller mean smarter ? [Poster presentation]. Séminaire Télévie 2024. |
Noronha, N., Durette, C., Cahuzac, M., E Silva, B., Courtois, J., Humeau, J., Sauvat, A., Hardy, M.-P., Vincent, K., Laverdure, J.-P., Lanoix, J., Baron, F., Thibault, P., Perreault, C., & Ehx, G. (2024). Autophagy degrades immunogenic endogenous retroelements induced by 5-azacytidine in acute myeloid leukemia. Leukemia, 38, 1019-1031. doi:10.1038/s41375-024-02250-6 |
E Silva, B., Zingoni, Z. M., Koekemoer, L., & Dahan-Moss, Y. (22 May 2021). Microbiota identified from preserved Anopheles. Malaria Journal, 20 (1). doi:10.1186/s12936-021-03754-7 |